We narrowed to 2,722 results for: LRE

#164510-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 (#164510). In addition to the viral particles, you will also receive purified pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 plasmid DNA. Synapsin-driven, cytosolic-targeted iGlucoSnFR-mRuby2

Loren Looger

Keller et al Cell Rep. 2021 Jun 22;35(12):109284. doi

Nov. 29, 2021

Academic Institutions and Nonprofits only

#98747-AAV5

Ready-to-use AAV5 particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 28, 2018

Academic Institutions and Nonprofits only

#98747-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#16399

Bert Vogelstein

He et al Proc Natl Acad Sci U S A. 1998 Mar 3. 95

June 11, 2008

Academic Institutions and Nonprofits only

#1000000104

Gateway entry vectors containing wildtype and mutant alleles associated with lung adenocarcinoma.

Jesse Boehm

April 24, 2017

Academic Institutions and Nonprofits only